221 related articles for article (PubMed ID: 22298599)
1. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
Morgan KP; Buie LW; Savage SW
Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
[TBL] [Abstract][Full Text] [Related]
2. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
Leu L; Baribeault D
J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?
Ruggiero A; Ariano A; Triarico S; Capozza MA; Romano A; Maurizi P; Mastrangelo S; Attinà G
J Oncol Pharm Pract; 2021 Jan; 27(1):180-186. PubMed ID: 32990190
[TBL] [Abstract][Full Text] [Related]
6. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
8. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
[TBL] [Abstract][Full Text] [Related]
9. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Al-Sarraf M; Fletcher W; Oishi N; Pugh R; Hewlett JS; Balducci L; McCracken J; Padilla F
Cancer Treat Rep; 1982 Jan; 66(1):31-5. PubMed ID: 6796269
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
13. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
14. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
15. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
16. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
El Hamamsy M; Kamal N; Bazan NS; El Haddad M
Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy.
Duffy EA; Fitzgerald W; Boyle K; Rohatgi R
Clin J Oncol Nurs; 2018 Apr; 22(2):175-183. PubMed ID: 29547601
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.
dos Santos NA; Carvalho Rodrigues MA; Martins NM; dos Santos AC
Arch Toxicol; 2012 Aug; 86(8):1233-50. PubMed ID: 22382776
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]